Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief People Officer Manuela Valente reported an open-market sale of 3,824 Ordinary Shares on April 8, 2026 at a weighted average price of $4.849 per share. According to the disclosure, the shares were sold to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026.
The filing states these sales were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After this transaction, Valente directly holds 215,451 Ordinary Shares of SOPHiA GENETICS SA.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported routine tax-related share sales. He sold a total of 4,849 Ordinary Shares in open-market transactions on April 8 and 9, 2026 at weighted average prices of $4.8452 and $4.7406 per share. According to the disclosure, these sales were made to satisfy tax withholding obligations from the vesting of restricted stock units under a pre-established Rule 10b5-1 trading plan and are not discretionary trades. After these transactions, he continues to hold 348,820 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza sold 1,403 ordinary shares of SOPH on April 8, 2026. The shares were sold in open-market transactions at a weighted average price of about $4.85 per share to cover tax withholding from recently vested restricted stock units.
According to the disclosure, these sales were made under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After these transactions, Cardoza directly holds 291,458 ordinary shares, indicating the sale represents a small portion of his overall position.
Morgan Stanley Smith Barney LLC reported a Form 144 disclosing sale activity by a holder associated with SOPH. The filing lists restricted stock units (1 RSU) with an award date of 04/02/2026 and three 10b5-1 sale transactions totaling 5,707 shares executed on 03/19/2026, 04/06/2026, and 04/07/2026.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported routine share sales tied to equity compensation taxes. He sold a total of 5,100 Ordinary Shares in open-market transactions on April 6 and 7, 2026 at weighted average prices of $4.8505 and $4.8653 per share.
According to the disclosure, these sales were made to satisfy tax withholding obligations arising from restricted stock unit vesting on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1 trading plan, rather than as discretionary trades. Following the sales, he directly holds 281,452 Ordinary Shares.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert sold 624 Ordinary Shares of SOPH in open-market transactions. The sales occurred on April 6, 2026 at prices around $4.86 per share and were executed solely to cover tax obligations from recently vested restricted stock units.
After these tax-related sales, Puylaert directly holds 148,230 Ordinary Shares, indicating that only a very small portion of his equity position was used for the "sell to cover" transactions, which the company describes as non-discretionary rather than voluntary market trades.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well sold 5,105 Ordinary Shares of SOPH in early April 2026. The sales, at weighted average prices of about $4.86–$4.87 per share, were made in the open market to cover tax withholding obligations from recently vested restricted stock units.
According to the disclosure, these transactions on April 6 and 7, 2026 were executed under a pre-established Rule 10b5-1 trading plan and are not discretionary trades. After the sales, Van Well continues to hold more than 350,000 Ordinary Shares directly.
SOPHiA GENETICS SA president Ross Muken sold 5,024 Ordinary Shares in two small open-market transactions to cover taxes on recent equity vesting. On April 6 and 7, 2026, he sold 2,600 shares at a weighted average of $4.8474 and 2,424 shares at $4.8686.
The footnotes state these sales were made to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026, under a pre-established Rule 10b5-1 trading plan and were not discretionary trades. After these sales, he continues to hold 698,097 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold a total of 5,100 Ordinary Shares of the company in early April 2026. The transactions were open‑market sales made solely to cover tax withholding obligations triggered by the vesting of restricted stock units on April 2 and 3, 2026, under a pre‑established Rule 10b5‑1 trading plan and were not discretionary trades. Camblong sold 2,600 shares on April 6 at a weighted average price of $4.8517 and 2,500 shares on April 7 at a weighted average price of $4.8619, and continued to hold about 3.73 million Ordinary Shares directly after these sales.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza reported small open-market sales of 4,933 Ordinary Shares to cover taxes on recent equity vesting. On April 6, he sold 2,520 shares at a weighted average price of $4.8456, followed by 2,413 shares on April 7 at a weighted average price of $4.8771. According to the disclosure, these trades were made under a pre-established Rule 10b5-1 trading plan and were executed to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. After these transactions, he continues to hold 292,861 Ordinary Shares directly, indicating the sales represent a small, routine portion of his overall stake.